NCT02842749CompletedPhase 4
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Locally Advanced, Unresectable or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China.
Source: ClinicalTrials.gov · Last updated 10 Feb 2025
Brief summary (registry, in English)
To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 61 (actual)
- First submitted
- 16 Jun 2016
- Start date
- 14 Mar 2016
- Primary completion date
- 22 Feb 2024
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Neuroendocrine tumours, Pancreatic cancer
- NCT number
- NCT02842749
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 61
- From 14 Mar 2016 to the primary completion date, 22 Feb 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior therapy with mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus).
- Use of an investigational drug within the 30 days prior to enrollment
Other illness
- Hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients.
Other
- Patient who is unwilling to receive Afinitor treatment due to any reason.
- Pregnant or nursing (lactating) women,
Who the study is looking for
- Patients must have histological confirmed G1 or G2 pancreatic neuroendocrine tumors(pNETs) (WHO 2010)
- Patients must have radiological documentation of progression of disease per RECIST 1.1 within 12 months prior to enrollment.
- Measurable disease per RECIST 1.1 criteria using triphasic computed tomography (CT) scan or multiphase MRI for radiologic assessment.
- everolimus treatment which is recommended by the treating physician
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| - Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| - Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.